Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Marlio Charles Mosseri Buys 240,000 Shares

Nuvectis Pharma, Inc. (NASDAQ:NVCT) major shareholder Marlio Charles Mosseri acquired 240,000 shares of the business’s stock in a transaction dated Friday, February 7th. The shares were bought at an average price of $5.00 per share, for a total transaction of $1,200,000.00. Following the completion of the acquisition, the insider now owns 2,884,121 shares in the company, valued at approximately $14,420,605. This trade represents a 9.08 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Marlio Charles Mosseri also recently made the following trade(s):

• On Friday, December 13th, Marlio Charles Mosseri purchased 17,000 shares of Nuvectis Pharma stock. The stock was acquired at an average price of $4.70 per share, for a total transaction of $79,900.00.

Nuvectis Pharma Stock Performance

NASDAQ NVCT opened at $6.29 on Wednesday. Nuvectis Pharma, Inc. has a one year low of $4.44 and a one year high of $12.10. The company’s 50 day moving average price is $5.63 and its 200 day moving average price is $6.34. The firm has a market capitalization of $121.52 million, a price-to-earnings ratio of -5.42 and a beta of 0.22.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of NVCT. Nations Financial Group Inc. IA ADV purchased a new position in Nuvectis Pharma in the third quarter valued at approximately $63,000. Oppenheimer & Co. Inc. purchased a new position in Nuvectis Pharma in the fourth quarter valued at approximately $135,000. GSA Capital Partners LLP raised its holdings in Nuvectis Pharma by 3.7% in the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock valued at $315,000 after buying an additional 1,790 shares during the period. Forbes J M & Co. LLP raised its holdings in Nuvectis Pharma by 21.9% in the fourth quarter. Forbes J M & Co. LLP now owns 59,000 shares of the company’s stock valued at $319,000 after buying an additional 10,599 shares during the period. Finally, Iridian Asset Management LLC CT purchased a new position in Nuvectis Pharma in the third quarter valued at approximately $348,000. Hedge funds and other institutional investors own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.